Showing results (171-180 of 200) with videos related to
Sort By:
Pageof 20
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1986
Tamoxifen versus placebo: double-blind adjuvant trial in elderly women with stage II breast cancerF J Cummings, R Gray, T E Davis, et al.Human Reproduction (Oxford, England)|July 1, 1997
Hydrosalpinges adversely affect markers of endometrial receptivityW R Meyer, A J Castelbaum, S Somkuti, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2000
Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypesW G Cance, J E Harris, M V Iacocca, et al.The Journal of Urology|November 1, 1990
Randomized phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium. The Eastern Cooperative Oncology GroupD L Trump, P Elson, S Madajewicz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1990
Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III studyH C Falkson, R Gray, W H Wolberg, et al.Prostaglandins, Leukotrienes, and Essential Fatty Acids|January 1, 1997
A 5-lipoxygenase inhibitor at micromolar concentration raises intracellular calcium in U937 cells prior to their physiologic cell deathT Buyn, P Dudeja, J E Harris, et al.Anticancer Research|September 1, 1996
An in vivo inhibitor of 5-lipoxygenase, MK886, at micromolar concentration induces apoptosis in U937 and CML cellsK M Anderson, T Seed, A Jajeh, et al.Prostaglandins, Leukotrienes, and Essential Fatty Acids|June 11, 2002
Increased cytosol Ca(2+) and type 1 programmed cell death in Bcl-2-positive U937 but not in Bcl-2-negative PC-3 and Panc-1 cells induced by the 5-lipoxygenase inhibitor MK 886K M Anderson, W A Alrefai, P K Dudeja, et al.Anti-Cancer Drugs|April 22, 1999
Conventional dose melphalan is inactive in metastatic melanoma: results of an Eastern Cooperative Oncology Group Study (E1687)H Hochster, M H Strawderman, J E Harris, et al.American Journal of Clinical Oncology|October 1, 1990
Phase II trial of carboplatin in soft-tissue sarcomaD Goldstein, B Cheuvart, D L Trump, et al.Pageof 20